Big news dropped Monday that most people in this space have been waiting on for months.
The New York Times is reporting that the FDA is preparing to lift compounding restrictions on roughly 14 of the 19 peptides that were moved to the Category 2 list back in 2023.
Reuters picked it up. NPR covered it. It's everywhere.
If this goes through, compounds like BPC-157, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, KPV, and others would move back to Category 1. That means licensed 503A compounding pharmacies could legally prepare them again under a physician's prescription.
Let me be clear about what this is and what it isn't.
This is not FDA approval. These are not going through Phase III trials. There are no standardized dosing guidelines coming out of this. What's happening is the FDA is reopening the door for licensed compounding pharmacies to prepare these compounds the way they're supposed to be prepared: under a doctor's order, for a specific patient, from a licensed pharmacy that follows quality and safety standards.
That distinction matters because right now the black market and gray market for peptides is a mess. Peptide Sciences shut down in March. People are buying research grade compounds from overseas vendors and injecting themselves with zero clinical oversight. That's the real safety problem. Not a licensed 503A pharmacy compounding under a prescriber's direction.
HHS Secretary Kennedy has been vocal about this since his Rogan appearance in late February, calling the original restrictions overreach and saying he personally uses peptides. Whether you agree with his politics or not, the regulatory direction is clear. Access is expanding. But access without compliance is just another version of the Wild West.
Here's what prescribers and clinic operators need to understand. If and when these peptides move to Category 1, the rules don't change. You still need a valid prescription. You still need a licensed compounding pharmacy. You still need clinical rationale and documentation. The compound has to be prepared for an individual patient based on a prescriber's determination.
The pharmacies that win in this next chapter are the ones that were already built for compliance. Not the ones scrambling to figure out how to add peptides to their menu because the market is hot.
We've been tracking this closely. If you want to understand what this means for your practice and your patients, reach out.
Here's what it actually means for you.
If you're a prescriber or clinic operator:
Category 1 status means licensed 503A compounding pharmacies can legally prepare these peptides again. BPC-157. Thymosin Alpha-1. CJC-1295. Ipamorelin. AOD-9604. KPV. The compounds your patients have been asking about for two years.
But reclassification is not FDA approval. Nothing changes about your responsibility. You still need clinical rationale. You still need to document why this patient needs this compound. You still need a licensed compounding pharmacy that meets quality and safety standards. The prescription still has to be patient-specific.
If you're already running a compliant practice with a compliant compounding partner, this opens up your formulary overnight. You can serve patients who were either going without or buying research grade peptides from unregulated sources online.
If you don't have that infrastructure in place yet, now is the time to build it. Not after the official announcement drops. Now.
If you're a patient:
This is good news. But it doesn't mean go buy peptides from a website that says "not for human consumption" on the label. That's the gray market. That's the problem this reclassification is trying to fix.
What it means is you can have a real conversation with your doctor about whether peptide therapy makes sense for you. And if it does, your doctor can write a prescription to a licensed compounding pharmacy that prepares it under proper quality controls. Sterility tested. Potency verified. Made for you specifically.
That's how this is supposed to work.
The black market exploded because the FDA restricted access and demand didn't go away. People found other ways to get these compounds, and a lot of those ways were dangerous. Moving these peptides back to Category 1 brings them back into the system where they belong. Under a doctor's care. From a licensed pharmacy. With actual oversight.
But here's the part nobody's saying loud enough.
Not every compounding pharmacy is the same. Reclassification doesn't make every compounder qualified to produce these compounds safely. Ask about their testing protocols. Ask about their state licenses. Ask about their track record. Your doctor should be asking these questions too.
Access is expanding. That's a win. But access without standards is just a different kind of risk.
If you're a prescriber figuring out how to add peptides to your practice the right way, or a patient looking for a provider who actually knows what they're doing, I'm happy to point you in the right direction.
About the Author
I work at the intersection of clinics, telehealth platforms, pharmacies, and the systems that support them.
I've spent the past decade building and scaling operations across clinics, telehealth platforms, and compounding pharmacies. I've seen practices succeed at 20 patients per month and break at 200. I've watched regulatory shifts reorganize entire markets overnight. I've built the infrastructure that determines whether modern therapies scale or stall.
This newsletter is about understanding how the system actually functions, where friction hides, and why some approaches compound over time while others don't.
If you're building, running, or participating in modern health in any real way, this layer matters more than most people realize.
"The system doesn't care about your intentions. It responds to what you built."
Until next time,
